^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ODC-IL2

    i
    Other names: ODC-IL2, ODC IL2, ODC Interleukin-2
    Associations

    News

    Trials
    Company:
    Boehringer Ingelheim, Trutino Biosci
    Drug class:
    IL-2 stimulant
    Related drugs:
    Associations

    News

    Trials
    3years
    [VIRTUAL] On demand cytokine, a novel cytokine prodrug, demonstrates robust single agent efficacy without systemic toxicity in syngeneic tumor models. (AACR 2021)
    Recombinant IL-2 (aldesleukin) is a potent T cell proliferation and differentiation factor and is an approved immunotherapy for advanced melanoma and renal cell carcinoma. Single agent efficacy of ODC-IL2 in subcutaneous syngeneic tumor models with diverse TME composition is shown. In conclusion, we have demonstrated proof of concept of the On Demand Cytokine platform and its potential to deliver safe and effective immunotherapies.
    Preclinical
    |
    CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2)
    |
    CD8 positive
    |
    Proleukin (aldesleukin) • ODC-IL2